Aberdeen Group
HLVX

Aberdeen Group’s HilleVax HLVX Stock Holding History

Aberdeen Group’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,000
Closed -$390K – 938
2024
Q2 		$390K Hold
27,000
– – ﹤0.01% 879
2024
Q1 		$449K Hold
27,000
– – ﹤0.01% 876
2023
Q4 		$433K Buy
+27,000
New +$359K ﹤0.01% 892

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Aberdeen Group's HLVX Position: Q3 2024 in Review

Aberdeen Group sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 27,000 shares — an estimated $390K sold.

Aberdeen Group first reported a position in HLVX in Q4 2023 and held it in 3 quarters. The position peaked at $449K in Q1 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • Aberdeen Group reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 27,000 HilleVax shares in Q3 2024, an estimated $390K.
  • Aberdeen Group first reported a position in HilleVax in Q4 2023 and held it in 3 quarters.
  • Aberdeen Group's HilleVax position peaked at $449K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.